Neurolief

Neurolief is a medical neurotechnology company developing non-invasive neuromodulation therapies for treating neurological and neuropsychiatric disorders such as migraine and major depressive disorder (MDD). Their flagship product, Relivion, is a wearable device that applies mild electrical pulses to six branches of the occipital and trigeminal nerves, stimulating the release of neurotransmitters in the brainstem and modulating brain networks associated with mood and pain.

The Relivion MG is designed for the acute treatment of migraine, providing an alternative to pharmaceutical therapies. In clinical trials, it demonstrated significant pain relief and freedom from migraine symptoms within two hours of treatment, with no serious adverse events reported. The device received FDA clearance and CE marking for acute migraine treatment. Neurolief is also pursuing approvals for migraine prevention and MDD treatment with their Relivion DP device.

The Relivion system incorporates a dedicated smartphone app and cloud database, allowing physicians to remotely monitor patients, analyze data, and personalize treatments. Neurolief launched a US Telehealth Channel in March 2023 to enhance patient access to the Relivion MG therapy, enabling online consultations and prescriptions within 24 hours.

Real-world analyses showed that 85% of patients achieved at least a 50% reduction in monthly migraine days using the Relivion MG, with a 71.1% reduction in acute medication use. In a six-month study, patients experienced a 65.3% decrease in monthly migraine days and a 76.8% reduction in daily acute medication consumption.